Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | C1S | P09871 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3093787 | 0.78 | MAOA (0.55) | MAOAALDH1A1MAPK1CA1CA2 | |
| SCHEMBL31275816 | 0.78 | MAOA (0.55) | MAOAALDH1A1MAPK1CA1CA2 | |
| SCHEMBL12778511 | 0.74 | ACHE (0.46) | ALDH1A1MAPK1DDB1CRBNLMNA | |
| SCHEMBL31412109 | 0.74 | MAOA (0.48) | MAOAALDH1A1MAPK1CA1CA2 | |
| SCHEMBL3289392 | 0.74 | MAOA (0.48) | MAOAALDH1A1MAPK1CA1CA2 | |
| SCHEMBL29543964 | 0.74 | MAOA (0.48) | MAOAALDH1A1MAPK1CA1CA2 | |
| SCHEMBL223379 | 0.74 | MAOA (0.48) | MAOAALDH1A1MAPK1CA1CA2 | |
| SCHEMBL31337906 | 0.74 | MAOA (0.48) | MAOAALDH1A1MAPK1CA1CA2 | |
| SCHEMBL13137670 | 0.74 | ALDH1A1 (0.38) | ALDH1A1MAPK1LMNAMAPTPKM | |
| SCHEMBL27925547 | 0.74 | MAOA (0.50) | MAOAALDH1A1MAPK1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2967073-B9 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-2967073-B9 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-2967073-B1 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-2967073-B1 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-01 | — | — | EP | disclosed |
| US-9834542-B2 | LXR modulators | BRISTO-MYERS SQUIBB COMPANY (US) | 2017-12-05 | — | — | US | disclosed |
| EP-2968275-B1 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-29 | — | — | EP | disclosed |
| EP-2968275-B1 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9751869-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751869-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751869-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160304499-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160304499-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160289222-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160289222-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160289222-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | US | disclosed |
| EP-2968275-A1 | LXR MODULATORS | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014144037-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144037-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289222-A1 | LXR MODULATORS | NR1H2, NR1H3, NR1H4 | MAOA 4278/4885ALDH1A1 2506/4885MAPK1 791/4885 |
| US-20160304499-A1 | LXR MODULATORS | NR1H2, NR1H3, NR1H4 | MAOA 4351/4885ALDH1A1 3047/4885MAPK1 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.